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A neuronal DNA damage response is detected at the earliest stages of Alzheimer’s
neuropathology and correlates with cognitive impairment in the Medical Research Council’s
Cognitive Function and Ageing Study ageing brain cohort
Aims: Population-based studies have shown that approxi-
mately 20% of the ageing population (aged 65 years and
over) with dementia have little or no classical Alzheimer-
type neuropathology. Cumulative DNA damage and a
reduced capacity of DNA repair may result in neuronal
dysfunction and contribute to cognitive impairment inde-
pendent of Alzheimer-type pathology in the ageing brain.
Methods: We investigated expression of the DNA damage
response (DDR)-associated molecules γH2AX and DNA-
PKcs using immunohistochemistry and western blotting,
and senescence-associated β-galactosidase in the frontal
association neocortex of cases with low levels of
Alzheimer-type pathology (Braak & Braak stage 0–II), and
explored their relationship to cognitive impairment in a
population-representative sample from the Medical
Research Council’s Cognitive Function and Ageing
Study cohort. Results: Increases in both γH2AX+
(rs = −0.36, P = 0.025) and DNA-PKcs+ (rs = −0.39,
P = 0.01) neuronal counts were associated with a lower
Mini-Mental State Examination score. Increasing levels of
senescence associated-β-gal+ pyramidal neurones were
weakly associated with the total number of DNA-PKcs+
neurones (P = 0.08), but not with traditional senescence-
associated signalling molecules, including p53 and p16.
Conclusion: The association between the neuronal DDR
and cognitive impairment, independent of AD pathology in
the ageing brain, may be suggestive of a causal link via
neuronal dysfunction.
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Introduction
Alzheimer’s disease (AD), the most common clinically
diagnosed subtype of dementia in the ageing population,
is classically characterized by extracellular deposits of
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β-amyloid and intracellular neurofibrillary tangles of
hyperphosphorylated tau. Population-based studies have
shown that approximately 20% of individuals with
dementia have little or no tangle pathology [1]. As life
expectancy continues to increase, so the burden of cogni-
tive impairment increases and with it a growing need to
identify, prevent and effectively treat dementia. Despite
large numbers of studies investigating the complex
molecular mechanisms underlying dementia, recent clini-
cal trials have failed to show efficacy [2]. There is a com-
pelling case to identify other potential factors contributing
to neuronal dysfunction and cognitive decline, either inde-
pendent of or interacting with classical AD lesions.
The Medical Research Council’s Cognitive Function and
Ageing Study (CFAS) is a large, well characterized,
population-representative, prospective, longitudinal study
of the ageing population in the United Kingdom that facili-
tates unbiased assessment of relationships between pathol-
ogy and dementia [1,3,4]. As cases are not pre-selected
according to clinical groups, population-based studies are
free from sampling bias and are essential for understanding
the association between disease and pathology, providing
complementary information to more classical case–
control designs [5]. The population approach of CFAS has
thus generated a number of insights into the biological
basis of dementia in a population setting, as reviewed [4,6].
CFAS has demonstrated an extensive overlap of Alzheimer-
type pathology (neurofibrillary tangles and plaques)
among demented and non-demented individuals [1],
which increases at the oldest ages [7]. This finding is sup-
ported by results from non-population-representative
studies [8,9] and suggests that factors other than classical
pathologies contribute to neuronal dysfunction and cogni-
tive impairment. However, the mechanisms that underlie
neuronal vulnerability, and which may initiate adverse
cellular processes many years before eventual cognitive
decline, are not fully understood and likely highly complex.
Recently, it has been proposed that processes that charac-
terize normal ageing, including mitochondrial dysfunc-
tion, telomere attrition and cellular senescence, are
interconnected and may contribute to neurodegeneration
[10]. These processes need to be explored in detail in the
ageing brain in order to fully understand relevant mecha-
nisms of neuronal dysfunction and cognitive impairment.
Oxidative stress is a feature of brain ageing that results
in the oxidative modification of proteins, lipids, DNA
and RNA [11,12] and plays a key role in several
neurodegenerative pathologies, including AD, Parkin-
son’s disease and motor neurone disease [13–15]. Oxida-
tive damage to nucleic acids is evident in mild cognitive
impairment (MCI) and early AD [16–18], suggesting that
oxidative stress is an early contributor to neuronal dys-
function which, either independently of or interacting
with early Alzheimer-type pathology, results in cognitive
impairment.
Oxidative DNA damage, in particular DNA double-
strand breaks, is a potent inducer of a DNA damage
response (DDR), which is characterized by the activation of
sensor kinases, including DNA-protein kinase catalytic
subunit (DNA-PKcs), and regions of DNA damage incorpo-
rating phosphorylated histone γH2AX [19]. Chronic oxi-
dative stress, a persistent DDR and telomere dysfunction
have all been implicated in the irreversible arrest of the cell
cycle resulting in cellular senescence [20]. Although
senescence is usually defined in the context of proliferation
arrest, a broader senescent phenotype is being defined with
cell-cycle arrest as one component that may not be essen-
tial to the definition. Recent studies of brain ageing have
demonstrated senescent human astrocytes [21,22] and
senescent mouse neurones [23] and suggest that cells with
a senescent phenotype may contribute to dysfunction of
the ageing brain. Activation of senescence-associated
β-galactosidase, a widely accepted general marker of the
senescent phenotype, is downstream of p53 and p21 in
ageing mice [23]. To date, the presence of senescent neu-
rones and the signalling pathway(s) involved in post-
mitotic neuronal senescence in the human brain are
unknown.
Previous investigation of the CFAS cohort has demon-
strated that high levels of oxidative stress and DNA damage
occur at the lowest Braak and Braak neurofibrillary tangle
stages, indicating that oxidative stress and the DDR are not
a late stage effect of established Alzheimer-type pathology
and may contribute to the development and progression of
age-related neurodegeneration [22]. We hypothesized
that, within an ageing population of individuals with little
AD neuropathology, high levels of oxidative stress and
neuronal DDR might contribute to neuronal dysfunction
and cognitive impairment. Therefore, in this study, we
defined the population variation in oxidative stress (lipid
peroxidation) and the neuronal DDR (γH2AX and DNA-
PKcs) in the frontal association neocortex of CFAS cases
with low levels of Alzheimer-type pathology, pre-selected
only by being at low (0–II) Braak and Braak neurofibrillary
tangle stage and investigated the relationship to dementia
status.
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Materials and methods
Human central nervous system (CNS) tissue
CNS tissue was obtained from MRC CFAS, following
Research Ethics Committee approval (REC ref 12/EM/
0118). Brains were donated as part of the CFAS study from
consented individuals. The structure of the CFAS neuropa-
thology cohort has been previously described and reviewed
[3,4]. Brains were dissected following a standard protocol
[24]. One cerebral hemisphere was fixed in formalin for a
minimum of 4 weeks, and the other hemisphere sliced in
the coronal plane, rapidly frozen and stored at −80°C.
Neuropathological lesions were assessed as part of the core
CFAS neuropathology study using a modified protocol from
the Consortium to Establish a Registry of Alzheimer’s
Disease [25] (http://www.cfas.ac.uk). Braak and Braak
staging for neurofibrillary tangle stage was assessed by
analysis of AT8 (detects tau phosphorylated at serine
199/202) immunostained sections of hippocampus and
isocortical regions [26]. This scheme identifies six stages
of neurofibrillary tangle progression, with hierarchical
involvement of entorhinal (stages I–II), limbic (stages
III–IV) and neocortical (stages V–VI) regions. The core
neuropathology assessment in CFAS also included semi-
quantitative assessment of diffuse and neuritic plaques,
vascular pathology, Lewy body pathology and other
identified lesions.
This study investigated Braak and Braak stage 0–II
cases from the CFAS cohort. Of this cohort, frozen frontal
cortex (FCx) was available for 39 cases from two CFAS
centres, one case with Pick’s disease was excluded on
review of the neuropathology, meaning 38 cases with an
average age at death of 82 years (range 70–102 years),
median post mortem delay of 19.2 h (IQR 18–24 h) and
tissue pH 6.6 (IQR pH 6.3–6.9) were used in the study. A
summary of the main neuropathological features of the
cohort is shown in Table 1.
Dementia status
Individuals in the study were regularly interviewed and
underwent Geriatric Mental State-Automated Geriatric
Examination for Computer-Assisted Taxonomy and Mini-
Mental State Examination (MMSE) [1,7], the interval
between last MMSE and death was 1.6 years, median 1.2
years. Dementia status at death was determined on the
basis of all information available for each participant
[1,27]. Within this cohort, 13 participants had dementia,
22 had no dementia and three participants had an
unknown dementia status at death due to the lack of
information in the years preceding death.
Western blot analysis
FCx samples were homogenized in Tris extraction buffer
(10 mM Tris-HCl pH 7.4, 0.8 M sodium chloride, 1 mM
ethylene glycol tetraacetic acid (EGTA), 10% sucrose,
0.1 mM phenylmethanesulphonylfluoride (PMSF),
2 μg/ml aprotonin, 10 μg/ml leupetin, 5 μg/ml pepstatin,
40 mM β-glycerophosphate, 50 mM sodium fluoride,
200 μM sodium orthovanadate) and centrifuged at
14 000 rpm for 30 min at 4°C. The protein content of the
supernatant was measured using the bicinchoninic acid
method and equal protein amounts (20 μg) analysed by
Table 1. Neuropathology of frontal cortex from low Braak and
Braak cases
Pathology No dementia Dementia
Braak stage
0 2 0
I 6 2
II 14 11
Neuritic plaques
None 18 10
Mild 2 2
Moderate 2 1
Diffuse plaques
None 11 5
Mild 5 4
Moderate 6 1
Severe 0 3
Parenchymal CAA
None 20 11
Mild 1 2
Meningeal CAA
None 19 10
Mild 2 0
Moderate 0 2
Infarcts*
Absent 18 7
Present 4 5
Haemorrhage*
None 21 12
Small vessel disease*
Absent 11 2
Present 11 11
*Based on global pathology scores from all assessed brain regions. No
cases in either group displayed neuronal loss, ballooned neurones,
severe gliosis, Lewy bodies, Pick bodies or spongiform changes.
CAA, cerebral amyloid angiopathy.
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western blot analysis. Proteins were separated by sodium
dodecyl sulphate-polyacrylamide gel electrophoresis (15%
for γH2AX, 8% for malondialdehyde (MDA) and 6% for
DNA-PKcs) and transferred to nitrocellulose (BioRad Labo-
ratory, Hemel Hempstead, UK). Membranes were incu-
bated overnight with rabbit anti-γH2AX (1:1000; R&D
Systems, UK), rabbit anti-MDA primary antibody (1:1000;
Cell Biolabs, Cambridge, UK) or mouse anti-DNA-PKcs
(1:500; Calbiochem, UK), followed by the appropriate
horseradish peroxidise-linked secondary antibody
(1:1000) and visualized by enhanced chemiluminescence
detection.To confirm equal protein loading, the membrane
was reprobed for β-actin (1:5000; AbCam, Cambridge,
UK). Protein expression levels were determined by
densitometry of the appropriate, sub-saturated band using
G:BOX Chemi (Syngene, Cambridge, UK) and the results
normalized to β-actin.
Immunohistochemistry
Immunostaining was performed using a standard avidin
biotinylated enzyme complex method, and the signal
visualized with diaminobenzidine (Vector Laboratories,
Peterborough, UK). A summary of the primary antibodies
used and their conditions for use is shown in Table 2.
Quantification of γH2AX+ and DNA-PKcs+
pyramidal neurones
Image capture of three adjacent 350 μm-wide cortical
ribbons through the full thickness of the FCx was per-
formed using Cell R software (Olympus Biosystems,
Watford, UK), using a × 20 objective. The image was
automatically thresholded and the total number of posi-
tive nuclei was quantitated using Analysis˄D software
(Olympus Biosystems, Watford, UK). The number of
DNA-PKcs+ or γH2AX+ positive pyramidal neuronal
nuclei was determined using a size exclusion of >250
pixels, and the number of positive small nuclei (glia and
small neurones) determined by subtracting the number
of pyramidal neuronal nuclei from the total number of
positive nuclei. To assess the total number of pyramidal
neurones and small cells in each case, an identical
quantitation protocol was performed on haematoxylin-
only stained serial sections. Therefore, in addition to total
counts of immunopositive neurones, the proportion of
immunopositive neurones was also determined by divid-
ing the number of positive neurones by the total number
of neurones in the FCx.
Semi-quantitative assessment of p53+ and
activated caspase-3+ pyramidal neurones
The number of p53+ neuronal nuclei was rated semi-
quantitatively using the × 20 objective as follows: no posi-
tive neuronal nuclei (none), 1–5 positive neuronal nuclei
(low), 5–20 positive nuclei (medium) and >20 positive
nuclei (high). Activated caspase-3+ pyramidal neurones
were rated semi-quantitatively as follows: no immunore-
active neurones (low), 1–5 positive neurones (medium),
>5 positive neurones (high).
Senescence-associated β-galactosidase
(SA-β-gal) activity
SA-β-gal activity was assessed using a senescence cells
histochemical staining kit (Sigma, Poole, UK). Briefly,
10 μm frozen sections were fixed with 2% paraformalde-
hyde for 6 min at RT. The sections were washed three times
with phosphate buffered saline (PBS) for 10 min at RT and
incubated overnight with freshly prepared SA-β-gal stain-
ing solution (pH 6) at 37°C in a humid chamber. The sec-
tions were washed three times with PBS for 10 min at RT,
counterstained with nuclear fast red, dehydrated through
Table 2. Antibody source and specificity
Antibody Isotype Dilution (time, temp) Supplier
DNA-PKcs Mouse IgG1 1:400 (60 min, RT) Calbiochem, UK
γH2AX Rabbit IgG 1:2000 (60 min, RT) R&D Systems, UK
caspase-3 Rabbit IgG 1:100 (60 min, RT) AbCam, UK
p16 (INK4) Mouse IgG Prediluted (o/n, 4°C) BioGenex, UK
p53 Mouse IgG2A 1:100 (60 min, RT) Santa Cruz, UK
o/n, overnight; RT, room temperature.
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a graded series of ethanol and cleared in xylene. Neuronal
expression of SA-β-gal was rated semi-quantitatively
using the × 20 objective in the cortical region of most
intense stain, as follows: no positive neurones (0); 1–5
positive cells (1); 5–20 positive cells (2); >20 positive neu-
rones (3).
Statistical analysis
Due to the small number of individuals, all tests were
undertaken using non-parametric methods but checked
for consistency using parametric regression models.
Spearman’s correlation coefficient was used to test
associations between continuous variables, with Mann–
Whitney U-Test, Kruskal–Wallis test for groups and non-
parametric trend test for ordered categories. SA-β-gal+
neurones were quantified by two independent observers
(JES and SBW) and the inter-rater reliability assessed
by calculating Cohen’s kappa coefficient. Analyses were
performed using STATA version 13 (StataCorp LP, College
Station, Texas, USA) and IBM® SPSS® Statistics 21
(Armonk, NY, USA).
Results
Population variation in oxidative stress and a
neuronal DDR
The population variation in lipid peroxidation and a DDR
was established using western blotting for MDA, γH2AX
and DNA-PKcs in total protein extracts from FCx
(Figure 1A–D, Table 3). Both MDA and γH2AX detected
single bands at 60 kDa and 17 kDa, respectively. Multiple
bands were detected in the DNA-PKcs immunoblot that
may represent DNA-PKcs degradation products, therefore
only the band at 480 kDa representing intact DNA-PKcs
was quantitated. MDA, DNA-PKcs and γH2AX protein
levels did not associate with each other and individuals
with the highest values for each marker did not corre-
spond (Figure 1E), suggesting that these markers behave
differently. Neither MDA nor γH2AX detection by western
blotting showed a relationship to brain pH or post mortem
delay (PMD) (all P > 0.2). Similarly, DNA-PKcs was not
associated with PMD but did show a significant associa-
tion with pH (rs = 0.50, P = 0.0012).
To determine whether oxidative stress and DNA damage
may result in processes leading to neuronal dysfunction
and injury, we sought to define the DDR in neurones using
immunohistochemistry. Specific nuclear immunostaining
of γH2AX and DNA-PKcs was associated with cells mor-
phologically resembling pyramidal neurones and glia
(Figure 2A,B). The number and proportion of γH2AX+
and DNA-PKcs+ neurones is shown in Table 4. The
number of γH2AX+ neurones significantly related to the
number of DNA-PKcs+ neurones (rs = 0.35, P = 0.03),
though this affect was attenuated for the proportion of
positive neurones (rs = 0.22, P = 0.19) as shown in
Figure 2C. No relationship was seen between γH2AX+ or
DNA-PKcs+ neurones and MDA western blot data, in
either the number or proportion of the immunopositive
neurones (all P values > 0.1).
Neuronal DDR is associated with a lower final
MMSE score
Both γH2AX+ (rs = −0.36, P = 0.025) and DNA-PKcs+
(rs = −0.39, P = 0.018) neuronal counts and proportions
(rs = −0.29, P = 0.07 and rs = −0.35, P = 0.03) were sig-
nificantly related to the patients’ last MMSE score
(Figure 3A,B); these results were unaffected by length of
time between last measured MMSE and death. Levels of
γH2AX+ and DNA-PKcs+ neurones were higher in cases
with dementia but did not reach significant levels
(P = 0.11 for γH2AX+ neuronal counts, P = 0.31 for pro-
portion of γH2AX+ neurones, P = 0.08 for DNA-PKcs+
neuronal counts, P = 0.11 for proportion of DNA-PKcs+
neurones) (Figure 3C,D). Cases with high γH2AX+
or DNA-PKcs+ neuronal counts (or proportion of
immunopositive neurones) were more likely to have a
lower final MMSE score than cases with lower γH2AX+ or
DNA-PKcs+ neurones.
No association between neuronal DDR and age,
sex, ApoE genotype, vascular pathology, diffuse
or neuritic β-amyloid plaques
Neither γH2AX+ nor DNA-PKcs+ neuronal counts (or pro-
portion of immunopositive neurones) were related to age
(Figure 4A), sex (Figure 4B), ApoE genotype (Figure 4C),
vascular pathology (Figure 4D), diffuse β-amyloid plaques
(Figure 4E) or neuritic β-amyloid plaques (Figure 4F) (all
P values > 0.2). Furthermore, there was no association of
either diffuse or neuritic β-amyloid plaques to the relation-
ship of DNA-PKcs or γH2AX and the individual’s last
MMSE score (all P values > 0.1).
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Figure 1. Population variation in lipid peroxidation and a DNA damage response. Representative western blot of (A) malondialdehyde,
(B) γH2AX and (C) DNA-PKcs expression in frontal cortex homogenates from Braak 0–II cases. (D) Densitometric analysis of all cases were
normalized to β-actin and expressed in densitometric arbitrary units (AUs). (E) 3D-scatterplot of protein levels. Cases with the highest levels
of MDA, γH2AX and DNA-PKcs and are shown in red, blue and yellow, respectively.
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Neuronal DNA damage is associated with
the induction of senescence-associated
β-galactosidase but not with activation of the
classical senescence signalling pathway
or apoptosis
SA-β-gal+ pyramidal neurones and small cells were present
throughout the FCx of the ageing brain (Figure 5A). Inter-
rater scores quantitating SA-β-gal+ neurones agreed for
58% of cases, and for the remainder differed by one cat-
egory (κ = 0.42, P < 0.001). Increasing levels of SA-β-gal+
pyramidal neurones were weakly associated with the total
number of DNA-PKcs+ neurones (P = 0.08), but there was
no association with either the proportion of γH2AX+ neu-
rones (counts and proportions P > 0.2) or DNA-PKcs+
neurones (P = 0.13). p16 immunoreactivity was exclu-
sively associated with astrocytes throughout the FCx
(Figure 5B). Relative scale measurements of p53+ pyrami-
dal neurones showed a statistically significant declining
trend with increasing DNA-PKcs+ neurones (counts
P = 0.007, proportions P = 0.006, Figure 5C,E) but not
γH2AX+ neurones (counts and proportions P > 0.2).
No association between activated caspase-3+ neurones
and DNA-PKcs+ or γH2AX+ neurones was detected
Table 3. Population variation in the expression of malondialdehyde and the DNA damage-related molecules γH2AX and DNA-PKcs at the
earliest stages of Alzheimer’s neuropathology, as detected by western blotting. Protein expression levels were determined by densitometry
and normalized to β-actin (densitometric arbitrary units)
MDA γH2AX DNA-PKcs
Number 38 38 38
Mean (SD) 1.08 (0.39) 1.99 (2.14) 1.21 (1.35)
Median (IQR) 1.0 (0.8–1.2) 1.15 (0.57–2.72) 0.54 (0.12–2.02)
IQR, inter-quartile range; SD, standard deviation.
Figure 2. Expression of DNA damage-related molecules. (A) γH2AX and (B) DNA-PKcs expression was associated with the nuclei of small
glia (arrow) and larger pyramidal neurones (arrow head). Scale bar represents 100 μm.
Table 4. Number and proportion of γH2AX+ and DNA-PKcs+ neurones in the FCx at the earliest stages of Alzheimer’s neuropathology
Neurones γH2AX Count Proportion DNA-PKcs Count Proportion
Mean (SD) 97.6 (9.3) 37.6 (19.5) 0.38 (0.19) 51.6 (24.4) 0.52 (0.23)
Median (IQR) 97.6 (91.3–103.5) 33.5 (29.1–44.1) 0.38 (0.28–0.48) 49.8 (35.3–69.8) 0.52 (0.38–0.66)
IQR, inter-quartile range; SD, standard deviation.
DNA damage response and cognitive impairment 489
NAN 2015; 41: 483–496© 2014 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd
on behalf of British Neuropathological Society
(Figure 5D,F), though numbers in the high group limit
statistical power despite some increase with γH2AX+ neu-
rones (all P values > 0.3).
Discussion
Previous work in MRC CFAS and other population-based
studies have shown that individuals whose cognitive
status is apparently discrepant when compared with con-
ventional pathological correlates of dementia (plaques,
tangles, vascular lesions, synucleinopathy) may represent
as much as 20% of the aged population [1]. Both high
pathology/normal cognition and low pathology/low cog-
nition states are encountered [1]. The majority of
dementia research focuses on cases selected on the basis
of clinical information and single pathologies or
clinicopathological diagnostic entities. Population-based
dementia studies, however, show that neuropathologies
commonly coexist and combine to produce cognitive
impairment and that the presence of classical hallmarks
of Alzheimer-type pathology, namely β-amyloid plaques
and neurofibrillary tangles, overlap so that classical
pathologies provide an incomplete pathological explana-
tion for dementia in the ageing population [1].
Population-based studies are therefore essential to iden-
tify novel biomarkers and to develop new therapeutic
strategies, complementing the case-control approach [5].
The present population-based study of individuals with
early Braak and Braak (entorhinal stage) cases, in which
tangles are restricted to mesial temporal lobe structures,
demonstrates that individuals with high levels of a
neuronal DDR are more likely to have lower MMSE
scores. These findings suggest, in some individuals, that
accumulation of DNA damage contributes to neuronal
dysfunction and cognitive impairment independent of
established Alzheimer pathology in the ageing brain. Fur-
thermore, this study shows an association between the
neuronal DDR and the expression of SA-β-gal in post-
mitotic neurones, but which is not associated with tradi-
tional senescence-associated signalling molecules.
Figure 3. Association of the neuronal DDR with cognitive impairment. Both (A) γH2AX+ and (B) DNA-PKcs+ neurones negatively
associated with the patients’ last MMSE score. (C) γH2AX+ and (D) DNA-PKcs+ neurones were higher in cases with dementia but did not
reach significant levels.
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Figure 4. Association of neuronal DDR with clinical information. γH2AX+ neurones did not show any association with (A) age, (B) sex,
(C) ApoE genotype, (D) vascular pathology, (E) diffuse β-amyloid plaques or (F) neuritic β-amyloid plaques.
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Figure 5. Expression of senescence and apoptosis-associated markers. (A) SA-β-galactosidase+, (B) p53+ and (C) activated caspase-3+
pyramidal neurones were detected in the ageing brain. (D) p16 was exclusively associated with astrocytes. Levels of (E) p53+ neurones
negatively associated with DNA-PKcs+ neurones but not (F) caspase-3+ neurones. Scale bar represents 50 μm in (A–C) and 100 μm in (D).
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An imbalance between levels of pro-oxidants and anti-
oxidants, in favour of the former, can result in oxidative
stress [12]. The brain has a limited DNA repair capacity
and is particularly susceptible to oxidative stress [28].
The oxidative stress theory of ageing proposes that a pro-
gressive and irreversible accumulation of reactive oxygen
species (ROS) above the clearance capacity of the cell
leads to DNA damage, mitochondrial dysfunction and
eventually cell death [29–32]. Oxidative stress can result
in lipid peroxidation and the generation of relatively
stable end-products including MDA, and the oxidative
modification of RNA and DNA bases. Several studies
have demonstrated significantly increased levels of MDA
in AD and MCI brains, particularly in regions associated
with a high prevalence of Alzheimer-type pathology
[33–35], and a disease-dependent increase in oxidative
markers localized to synapses in post mortem FCx from
MCI and late-stage AD patients [36]. In contrast,
other studies have shown that levels of lipid peroxida-
tion markers, oxidized nucleosides and nucleotides
inversely correlate with neurofibrillary tangle content
[17,18,22,37], suggesting that oxidative stress and oxi-
dative damage to DNA and RNA is an early event in AD
pathology. Our data demonstrate the extent of popula-
tion variation in lipid peroxidation and the DDR at low
Braak and Braak stages, and support the alternative
model of neuronal loss in AD proposed by Nunomura
et al., in which oxidative stress occurs before the forma-
tion of plaques and tangles and causes neuronal dys-
function [38], in the ageing population. It is likely that
widespread DNA damage resulting from increased oxida-
tive stress and a decreased ability to repair DNA damage
triggers this neuronal dysfunction ultimately leading to
cognitive impairment.
A significant correlation between levels of oxidative
stress markers and MMSE has been previously reported
[36], supporting this study’s findings that individuals with
high levels of a neuronal DDR are likely to have signifi-
cantly lower MMSE scores and have dementia. The lack of
significant association with dementia in the study likely
reflects cohort size and a reduced power to detect an effect
based on the comparison of 13 demented cases to 22 non-
demented cases. In contrast, an MMSE score was available
for all the cohort. Although recent studies have demon-
strated an increased vulnerability to oxidative damage in
AD and MCI patients with the ApoEε4 allele [39,40], we
did not detect any correlation between the neuronal DDR
and ApoE genotype in the cohort.
The detection of SA-β-gal+ neurones and their weak
association with the total number of DNA-PKcs+ neurones
in the ageing brain supports a recent study that demon-
strated that the accumulation of DNA damage can induce
a senescence phenotype in mature, post-mitotic neurones
in ageing mice and confirm that senescence is not
restricted to proliferating cells [23]. Senescent cells
produce and secrete a range of molecules including pro-
inflammatory cytokines and pro-oxidants [41] and can
induce a DDR in neighbouring cells in vitro [42], suggest-
ing a mechanism whereby this change in phenotype may
underlie neuronal dysfunction in the ageing brain. This
may operate either through dysfunction of the neurones
themselves, where cells that appear viable may be ‘zombie
cells’ that do not function normally, or by impairing their
interaction with other cell types, such as the neuronal
regulation of microglia.
Although DNA-PKcs is constitutively expressed by most
cell types [43], an increase in DNA-PKcs expression is
associated with neurones within infarcts [44], whereas a
reduction in expression is associated with acute CNS
injury due to ischaemia [45] and established AD, as
recently reviewed [46]. Levels of DNA-PKcs are regulated
by post-transcriptional and post-translational mecha-
nisms [43], including regulation by p53-inducible gene 3
(PIG3) [47]. p16 and p53 play a critical role in the induc-
tion of cell senescence in vitro, as recently reviewed
[10]. Overexpression of p16 induces cellular senescence
[48,49], whereas activation of the p53 signalling
pathway may protect neurones from DNA damage
through cell cycle arrest and the induction of DNA repair,
or trigger cellular senescence or result in apoptosis [50].
However, in this study, we did not detect a relationship
between the neuronal DDR and these traditional
senescence-associated signalling molecules. p16 was not
expressed by neurones and was exclusively associated
with cells with an astrocytic morphology. Neuronal p53
expression was inversely related to DDR, suggesting a
response to persistent DNA damage in neurones involving
decreased p53 levels to prevent apoptosis and promote
cell survival. The signalling pathway(s) responsible for
the induction of neuronal senescence and the role of
neuronal senescence in the ageing brain remain
unknown, but it is likely that this change in phenotype
contributes to neuronal dysfunction, ultimately resulting
in cognitive decline in the ageing population.
In research performed on post mortem material, the
possibility of artefacts due to post mortem delay and/or
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brain pH must be considered. A study examining the
effects of PMD on measures of oxidative damage reported
similar levels between cases with a short post mortem
interval and those with a longer interval [51]. We report
that neither levels of oxidative stress nor the DDR were
associated with PMD. However, DNA-PKcs detection was
associated with brain pH, but it should be noted that this
was a positive association, the opposite of what would
have been predicted if a poor premorbid state, which is
accompanied by low brain pH, induced DNA-PKcs
expression.
In summary, we have defined the molecular signature of
a neuronal DDR that significantly associates with cogni-
tive impairment in older individuals with only early stage
Alzheimer-type pathology. We also demonstrate that this
is associated with markers of a senescent phenotype in
these post-mitotic cells. As these individuals were at only
the lowest Braak and Braak stages, this neuronal DDR is
not attributable to established AD. It may be independent
of Alzheimer’s or interact with the earliest molecular
stages of the disease. This remains to be resolved, but its
association with cognition suggests that oxidative stress
and the associated DDR is a potentially important line of
investigation in its own right, rather that solely part of the
pathogenesis of AD. Furthermore, cognitive decline in
brain ageing may involve a complex interaction of specific
pathological entities with ageing processes. Future work
to characterize the effects of oxidative DNA damage on the
neuronal molecular profile, and any interaction with
similar processes in the glial cell populations, will poten-
tially reveal novel dementia biomarkers, cellular pathways
and specific therapeutic targets.
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Figure S1. Association of neuronal DDR with clinical
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neuritic β-amyloid plaques.
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